Related references
Note: Only part of the references are listed.Crosstalk between β-catenin and WT1 signaling activity in acute myeloid leukemia
Megan Wagstaff et al.
HAEMATOLOGICA (2023)
Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
Hikaru Minagawa et al.
BMC CANCER (2023)
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide
Tomoki Naoe et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study
Bhavana Bhatnagar et al.
BLOOD ADVANCES (2023)
Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant
Siba El Hussein et al.
BONE MARROW TRANSPLANTATION (2022)
Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial
Toru Kiguchi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Tumor suppressor function of WT1 in acute promyelocytic leukemia
Matthew J. Christopher et al.
HAEMATOLOGICA (2022)
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma
Rosa A. van Amerongen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience
Veronika Valkova et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis
Urbi Roy et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
Dao-Xing Deng et al.
BMC CANCER (2021)
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS
Christina Rautenberg et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
Juliette Lambert et al.
BLOOD ADVANCES (2021)
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
Alexander Spira et al.
TARGETED ONCOLOGY (2021)
Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1
Sandeep Potluri et al.
CELL REPORTS (2021)
Wilms Tumor 1 Mutations Are Independent Poor Prognostic Factors in Pediatric Acute Myeloid Leukemia
Yin Wang et al.
FRONTIERS IN ONCOLOGY (2021)
WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes
Valentina Giudice et al.
BIOMEDICINES (2021)
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
Christian Augsberger et al.
BLOOD (2021)
WT1 inhibits AML cell proliferation in a p53-dependent manner
Yiyun Yao et al.
CELL CYCLE (2021)
Curcumin attenuates Adriamycin-resistance of acute myeloid leukemia by inhibiting the lncRNA HOTAIR/miR-20a-5p/WT1 axis
Jun-Min Liu et al.
LABORATORY INVESTIGATION (2021)
Effect of Down-Regulation of miR-23b-3p on the Differentiation of Acute Myeloid Leukemia via Wilms Cancer Gene 1
Lixia Cao et al.
JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING (2021)
A Novel HAGE/WT1-ImmunoBody(R) Vaccine Combination Enhances Anti-Tumour Responses When Compared to Either Vaccine Alone
Rukaia Almshayakhchi et al.
FRONTIERS IN ONCOLOGY (2021)
Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia
Bianhong Wang et al.
HEMATOLOGY (2021)
Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia
Ya-Zhen Qin et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia
Xiao-Rui Wang et al.
ANNALS OF HEMATOLOGY (2020)
The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients
Mirjana Mitrovic et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)
Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions
Ping Luo et al.
LEUKEMIA & LYMPHOMA (2020)
WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia
Cyril Salek et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation
Maud Plantinga et al.
FRONTIERS IN IMMUNOLOGY (2020)
Wilms' tumor gene (WT1) expression levels as prognostic marker in pediatric acute lymphoblastic leukemia
Neveen L. Mikhael et al.
EGYPTIAN JOURNAL OF HAEMATOLOGY (2020)
WT1 overexpression predicted good outcomes in adult B-cell acute lymphoblastic leukemia patients receiving chemotherapy
Shujuan Wang et al.
HEMATOLOGY (2020)
The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission
Kentaro Ido et al.
TRANSPLANTATION (2019)
Wilms Tumor-1 (WT1) rs16754 Polymorphism and Clinical Outcome in Acute Myeloid Leukemia
Mani Ramzi et al.
TURKISH JOURNAL OF HEMATOLOGY (2019)
WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates
Byung-Sik Cho et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
Aude G. Chapuis et al.
NATURE MEDICINE (2019)
Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia
Naghmeh Niktoreh et al.
JOURNAL OF ONCOLOGY (2019)
Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS
Christina Rautenberg et al.
BLOOD CANCER JOURNAL (2019)
Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial
Hee-Je Kim et al.
BONE MARROW TRANSPLANTATION (2019)
Co-activation of WT1 and AP-1 proteins on WT1 gene promoter to induce WT1 gene expression in K562 cells
Songyot Anuchapreeda et al.
CELLULAR SIGNALLING (2019)
Study of Wilms' tumor 1 gene expression in patients with acute myeloid leukemia
Ebtesam Ahmad et al.
EGYPTIAN JOURNAL OF HAEMATOLOGY (2019)
Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
Qiu-Sha Huang et al.
BLOOD ADVANCES (2019)
WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia
Fulvio Bordin et al.
HAEMATOLOGICA (2018)
Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine
Toshiro Shirakawa et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia
Fulvio Bordin et al.
HAEMATOLOGICA (2018)
Retrospective Analyses of Wilms Tumor Gene-1 Expression in Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
Seara Ikeno et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value
Josep F. Nomdedeu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation
Christina Rautenberg et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study
Daisuke Hidaka et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Role of the Wilms' Tumor Suppressor Gene Wt1 in Pancreatic Development
Laura Ariza et al.
DEVELOPMENTAL DYNAMICS (2018)
DNA and RNA binding by the Wilms' tumour gene 1 (WT1) protein +KTS and -KTS isoformsFrom initial observations to recent global genomic analyses
Tove Ullmark et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA
Feng-Ming Tien et al.
HAEMATOLOGICA (2018)
Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia
S. Wang et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2018)
Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia
Jessica Petiti et al.
LEUKEMIA RESEARCH (2018)
Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA
Feng-Ming Tien et al.
HAEMATOLOGICA (2018)
Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse
Kiyomi Mashima et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
The genetic basis and cell of origin of mixed phenotype acute leukaemia
Thomas B. Alexander et al.
NATURE (2018)
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology
Carolina Martinez-Laperche et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Measurable Residual Disease Assay with WT1 Expression in Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation; Optimal Threshold, Time Points, and Candidates
Byung Sik Cho et al.
BLOOD (2018)
Wilms' tumor gene 1 expression can predict sudden disease progression to blast crisis in patients with chronic myeloid leukemia receiving imatinib therapy
Mohamed A. M. El-Menoufy et al.
EGYPTIAN JOURNAL OF HAEMATOLOGY (2018)
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
Peter G. Maslak et al.
BLOOD ADVANCES (2018)
Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group
Alice Marceau-Renaut et al.
HEMASPHERE (2018)
Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome
Joji Nagasaki et al.
ACTA HAEMATOLOGICA (2017)
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima et al.
NATURE GENETICS (2017)
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia
Anna Candoni et al.
EXPERIMENTAL HEMATOLOGY (2017)
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia
Fabio Guolo et al.
HAEMATOLOGICA (2017)
High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
Jae-Ho Yoon et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and - independent pathways
Y. Lyu et al.
LEUKEMIA (2017)
WT1 MRNA EXPRESSION IS A GOOD LABORATORY INDICATOR FOR DIAGNOSIS OF DISEASE PROGRESSION IN MDS PATIENTS WITH STABLE DISEASE
X. Du et al.
LEUKEMIA RESEARCH (2017)
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission
Anna Candoni et al.
LEUKEMIA RESEARCH (2017)
Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study
Chiara Frairia et al.
LEUKEMIA RESEARCH (2017)
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
Jewell N. Walters et al.
MOLECULAR THERAPY (2017)
Regulation of HtrA2 on WT1 gene expression under imatinib stimulation and its effects on the cell biology of K562 cells
Lixia Zhang et al.
ONCOLOGY LETTERS (2017)
The Wilms’ tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis
Yanan Jiang et al.
Oncotarget (2017)
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia
Fabio Guolo et al.
HAEMATOLOGICA (2017)
Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
Yasunori Ueda et al.
CANCER SCIENCE (2017)
The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells
Rassanee Bissanum et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
WT1 heteroclitic epitope immunization following autologous stem cell transplantation in patients with high-risk multiple myeloma (MM).
Guenther Koehne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS
Isao Tawara et al.
BLOOD (2017)
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Sebastien Anguille et al.
BLOOD (2017)
Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients
Irena Marjanovic et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?
Federico De Marchi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?
Jae-Ho Yoon et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML
R. Dulery et al.
BONE MARROW TRANSPLANTATION (2017)
Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells
Tove Ullmark et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia
J. E. Megias-Vericat et al.
PHARMACOGENOMICS JOURNAL (2016)
Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience
Gholamreza Toogeh et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia
Raajit Rampal et al.
HAEMATOLOGICA (2016)
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia
Raajit Rampal et al.
HAEMATOLOGICA (2016)
A role of WT1 in cell division and genomic stability
Jayasha Shandilya et al.
CELL CYCLE (2015)
Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis
Xiao-wei Qi et al.
SCIENTIFIC REPORTS (2015)
Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair
Yusuke Oji et al.
MOLECULAR CARCINOGENESIS (2015)
Wt1-expressing progenitors contribute to multiple tissues in the developing lung
Elena Cano et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2013)
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
Aude G. Chapuis et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences
K. Kramarzova et al.
LEUKEMIA (2012)
The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis
You-Ying Chau et al.
TRENDS IN GENETICS (2012)
WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system
Hsin-An Hou et al.
BLOOD (2010)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
Daniela Cilloni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance
Coralie Chaise et al.
BLOOD (2008)
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy
Daniela Cilloni et al.
HAEMATOLOGICA (2008)
Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells
E. Svensson et al.
LEUKEMIA (2007)
Wt1 and retinoic acid signaling are essential for stellate cell development and liver morphogenesis
A. Ijpenberg et al.
DEVELOPMENTAL BIOLOGY (2007)
Antiapoptotic function of 17AA(+) WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway
K. Ito et al.
ONCOGENE (2006)
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
Y Oka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow
JP van Dijk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies
OA Elisseeva et al.
BLOOD (2002)
The Wilms' tumor gene Wt1 is required for normal development of the retina
KD Wagner et al.
EMBO JOURNAL (2002)
Cancer immunotherapy targeting Wilms' tumor gene WT1 product
Y Oka et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
